Two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease areas—first-line non-small cell lung cancer (NSCLC).
What does everyone think of this?
Bristol Myers Lag-3 drug into phase 3 trials in first-line lung cancer field
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.8¢ |
Change
-0.008(3.06%) |
Mkt cap ! $348.6M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 23.5¢ | $194.6K | 810.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 365780 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 334856 | 28 |
View Market Depth
| Last trade - 13.55pm 09/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |